WuXi PharmaTech Strikes Deal with Pacific Biomarkers

WuXi PharmaTech will collaborate with Pacific Biomarkers (PBI) of Seattle by offering PBI’s validated biomarker assays to WuXi's clinical-stage CRO clients. PBI’s services will include bioanalysis and central laboratory services for biopharmas engaged in China clinical drug trials. According to WuXi, PBI’s biomarker expertise complements its own capabilities. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //